(2019). … The other 75 R&D projects target other diseases in scope. If you are in the US and would like additional information regarding AstraZeneca drugs, please contact the Information Center at AstraZeneca at 1-877-893-1510 1-877-893-1510. Our focus is to transform the lives of the millions of patients living with metabolic diseases. Important notice for users Prevention: Heart attack. Healthy Heart Africa is committed to tackling hypertension and the increasing burden of cardiovascular disease (CVD) in Africa. AstraZeneca provides this link as a service to website visitors. Around one in three patients with acute coronary artery disease (CAD) is estimated to have type-2 diabetes (T2D), and patients with both CAD and diabetes are at almost double the risk for a major adverse cardiovascular event compared to diabetes patients with only risk factors for cardiovascular disease.6,7, In addition, the more risk factors that a patient with a prior heart attack may have – such as diabetes, multivessel disease or chronic kidney disease – the greater the chance of experiencing an event.8, In the US, about 33-46% of the patients with end-stage renal disease have cardiovascular disease (CVD) and about 28-44% have heart failure.9 The presence of CVD is associated with worsening short and long-term survival of end-stage kidney disease patients after a cardiovascular procedure with CVD being a leading cause of death in those patients.10. Fox KA, et al. Underestimated and under-recognized: the late consequences of acute coronary syndrome (GRACE UK–Belgian Study). Available from URL: Roth G, et al. This website is intended for people seeking information on AstraZeneca's worldwide business. Burden of cardio-renal-metabolic conditions in adults with type 2 diabetes within the Diabetes Collaborative Registry. SVP, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, Measuring blood flow changes in coronary arteries aids application of targeted heart disease therapies to improve patient outcomes, Hope for CKD: Proactive Prevention and Detection Strategies, Making chronic kidney disease a policy priority, Understanding the journey of care for patients with cardiovascular, renal and metabolic disease, https://www.who.int/cardiovascular_diseases/world-heart-day/en/, https://www.niddk.nih.gov/health-information/health-statistics/kidney-disease, https://www.ahajournals.org/doi/full/10.1161/CIR.0000000000000395, Accepted You have selected a link that will take you to a site maintained by a third party who is solely responsible for its contents. cardiovascular and metabolic diseases. To tackle key issues in cardiovascular care and associated complications, AstraZeneca has entered a multi-year partnership with World Heart Federation (WHF), the world’s leading voice for cardiovascular health. 2010;31(22):2755-64. Impact of Diabetes Mellitus on Hospitalization for Heart Failure, Cardiovascular Events, and Death: Outcomes at 4 Years from the Reduction of Atherothrombosis for Continued Health (REACH) Registry. Edelman Intelligence Relevance and barriers amongst EU specialists Survey 2018. Our advanced approach to Regulatory means we are leading the field. 2004;25(21):1880–90. AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development, and commercialization of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, … Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. Shiba N, Shimokawa H. Chronic kidney disease and heart failure--Bidirectional close link and common therapeutic goal. World Health Organization. Life After a Heart Attack. We are exploring treatment options to reduce cardiovascular problems and death in high-risk patients, beyond acute coronary syndrome. dapagliflozin and metformin HCI extended-release. Our focus is to transform the lives of the millions of patients living with metabolic diseases. Eur Heart J 2015; 36:1163-1170. Heart failure drug Farxiga has just received approval from the FDA, providing the potential to treat million of people in the United States. 2017;70(1):1-25. Heart attack and unstable angina pectoris, are responsible for almost half of all deaths related to cardiovascular disease worldwide. You are about to access AstraZeneca historic archive material. The acquisition continues AstraZeneca’s track record of targeted business development with a focus on three main therapy areas. Chronic kidney disease occurs in the context of multiple comorbidities and has been termed as a “disease multiplier.”11 We work to find ways to help patients manage the many complications and provide solutions for better disease management. (Monday to Friday, 8 AM to 6 PM ET, excluding holidays. 12. 8. For all Medical Information enquiries, about the AstraZeneca COVID-19 vaccine and to view the Information for UK Vaccine Recipients and Information for Healthcare Professionals please click here.. You have selected a link that will take you to a site maintained by a third party who is solely responsible for its contents. American Heart Association. AstraZeneca’s deep pipeline of medicines focusing on their key therapeutic areas. AstraZeneca plc. Our ambition is to eliminate the remaining cardiovascular (CV) risk of patients with CV disease and stopping disease progression, therefore preventing CV events from occurring and protecting the lives of millions of patients. Heart disease or coronary artery disease (CAD) is a chronic and persistent condition in which the arteries that supply the heart with blood are narrowed.4,5 Atherosclerotic plaque, a build-up of deposits of fatty material, cholesterol, cellular waste products and other substances, accumulate in the coronary arteries, obstructing the blood flow to the heart muscle.5 The plaque can cause a partial or complete blockage of blood supply to the heart muscle, which can cause a heart attack.4,5, We are seeing that patient therapy goes beyond treating one disease. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: A systematic analysis for the Global Burden of Disease Study 2015. Our commitment to cardiovascular care began with one of the first oral antihypertensive medications in the 1950s and continued with research leading to new cholesterol-lowering statins in the 1970s. 2014 August ; 21(4): 279–286. Heart attack. We aim to treat life-threatening complications and halt disease progression to provide millions of patients living with chronic kidney disease with a longer and greater quality of life. Narisa Futrakul, Ankanee Chanakul, Prasit Futrakul & Tawatchai Deekajorndech (2015) Early stage of vascular disease and diabetic kidney disease: an underrecognized entity, Renal Failure, 37:8, 1243-1246, DOI: 10.3109/0886022X.2015.1073054. We strive to prevent heart disease onset, as well as treat and regenerate the heart to help protect millions of people living with heart failure. We encourage you to read the privacy policy of every website you visit. I have read this warning and will not be using any of the contained product information for clinical purposes. 2015. Veeva ID: Z4-25396Date of next review: August 2022. Click ‘cancel’ to return to AstraZeneca’s site or ‘continue’ to proceed. Omnichannel marketing is a customer centric approach that allows AstraZeneca to interact with our Healthcare Physicians (HCPs) and Consumers seamlessly across all available channels, delivering a more integrated, informed and connected customer experience – one that drives values for both AstraZeneca and our customers. Developed with the American College of Cardiology (ACC), the Program successfully reduced the readmission rate among primary HF inpatients by using a patient-tailored approach.19, GULLIVE-R (GUideline adherence and risk assessment after acute myocardiaL infarction in real LIfe in Germany – a quality improVEment and awareness Registry of the German Cardiac Society) is a real-world evidence registry following patients from up to 250 hospitals and office-based centres in Germany for 9 to 18 months post-MI. Today, we strive to meet even greater expectations by offering options for patients and healthcare providers. Presented at: ESC Congress 2018, 2018 Aug 25-29, Munich, Germany. AstraZeneca has a total of 79 R&D projects featuring a small-sized priority R&D pipeline compared to its peers: 4 projects. We aim to save the lives of people who suffer from cardiovascular disease, heart failure, chronic kidney disease and diabetes, by advancing CVRM solutions and addressing shared risk factors between these distinct but interrelated disease areas. AstraZeneca UK aims to support local innovation and best practice that improves patient care in Respiratory, Immunology, Cardiovascular, Metabolic, Renal and Oncology therapy areas. 13. Knuuti J et al. 6. Available from URL: National Health Service. AstraZeneca has sales in 67 countries in scope. Zeymer, U. Our country sites can be located in the AZ Network. This collaboration expands compliance with evidence-based guidelines across China. European Heart Journal (2013) 34, 3035–3087 doi:10.1093/eurheartj/eht108. 10. Together with key experts throughout the world we collaborate to accelerate our scientific progress, and to further define patient populations that may benefit from the novel cardio-renal-metabolic therapies we are developing. Eur Heart J 2019. Important notice for users Liviu Segall, Ionut Nistor, and Adrian Covic, “Heart Failure in Patients with Chronic Kidney Disease: A Systematic Integrative Review,” BioMed Research International, vol. 7. 2019]. We are agnostic to drug modality, we identify and validate novel targets based on genetics and human target validation and then apply the best modality to modulate the target. We are advancing a pipeline of inhaled and biologic treatments, drug combinations and devices, and other therapies that aim to transform disease management. Heart disease or coronary artery disease (CAD) is a chronic and persistent condition in which the arteries that supply the heart with blood are narrowed. Heart disease or coronary artery disease (CAD) is a chronic and persistent condition in which the arteries that supply the heart with blood are narrowed. Cardiovascular disease. 2015;36(19):1163–70. Please refer to your approved national product label (SmPC) for current product information. 's AZN stock has rallied 11.9% this year so far, outperforming the industry's rise of 3.7%. The Microbial Sciences group at AstraZeneca is studying the impact of the microbiome on the host immune response and its potential role in driving chronic disease. Cavender MA, et al. Association of key risk factors and their combinations on ischemic outcomes in patients with invasively managed myocardial infarction in Sweden. Kidney Disease Statistics for the United States: December 2016. Entering a new era in vascular and cardiac regeneration research As we move novel therapeutic modalities from the laboratory into clinical trials, we are focusing on the repair and regeneration of tissues with the potential to treat life threatening cardiovascular diseases such as heart failure. In our first co-initiative with WHF, we are supporting people with cardiovascular disease and its complications who are at a higher risk of severe complications of COVID-19 by providing them with the much-needed advice and resources on their risk and how to manage their condition and stay healthy during the pandemic. Circulation 2016; 133:e674-e690. Geneva, Switzerland: World Economic Forum (cited 2018 Aug 6). In 2017, our respiratory medicines reached more than 18 million patients. Document ID: Z2-0050 | Date of preparation: August 2018 | Date of expiry: July 2020. Since 2014, there has been a 75% compliance rate among those hospitals involved. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. We aspire to move healthcare professionals to treat beyond HbA1C, prevent early cardiovascular and renal complications and explore non-alcoholic steatohepatitis (NASH). March 25, 2020 AstraZeneca has announced a collaboration with UK biotech Silence Therapeutics to develop gene silencing drugs for cardiovascular, renal, metabolic and respiratory diseases. 2010;304(12):1350-7. The disease areas we’re targeting include rheumatology (including type 1 interferon-driven diseases such as lupus), dermatology, gastroenterology and systemic eosinophilic-driven diseases. Programme screening and treatment & Total programme KPIs. Available from URL: American Heart Association. There are a few other important lifestyle changes patients can make to help reduce the risk of experiencing a second episode and help ease their worry: of all global deaths are caused by cardiovascular diseases1, of people who were event-free for the first year after a myocardial infarction, experienced a second cardiovascular event within a 3-year period3, in global cost of cardiovascular disease, from $863 billion in 2010 to $1.04 trillion in 203018, in incidence of subsequent CV events (in patients who’ve previously had a heart attack) if five cardiovascular risk factors are present (+65 years, chronic kidney disease, diabetes, multivessel disease, prior MI) compared to patients with only one risk factor8. Available from URL: Healthtalk.org. 2018. The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. This partnership will see us work hand-in-hand on global policy, advocacy and disease awareness initiatives, supporting global and local activations to assist those at particularly high risk. Any reference in these archives to AstraZeneca products or their uses may not reflect current medical knowledge and should not be used as a source of information on the present product label, efficacy data or safety data. Our enduring goal is to push the boundaries of science to further reduce cardiovascular morbidity and mortality beyond current treatments, and to deliver transformative cardiovascular medicines to the people who need them. Neues Versorgungsforschungsprojekt GULLIVE-R zur Langzeitversorgung von Herzinfarkt-Patienten in Deutschland. Atherosclerosis; 2017 [cited 2019 Feb 19]. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective. Pipeline. At the end of 2015, the company bought Takeda’s res-piratory business for USD 575 mn. DGK Pressemitteilung, 25. AstraZeneca is not responsible for the privacy policy of any third party websites. My accountability includes research and development through clinical proof-of-concept for our CVRM pipeline, with a focus on disease modification, regenerative medicine and precision medicine. WHO World Heart Day: Scale up prevention of heart attack and stroke: World Health Organization. Available from: URL: https://www.heart.org/en/health-topics/cholesterol/about-cholesterol/atherosclerosis. AstraZeneca data on file. COVID-19 Vaccine AstraZeneca is a vaccine used to protect people aged 18 years and older against COVID-19. April 2019. Veeva ID: Z4-25396Date of next review: August 2022. JernBerg T et al. ZS Pharma represents a strong fit with AstraZeneca’s pipeline and portfolio in Cardiovascular & Metabolic Disease, one of the company’s three main therapy areas. Nakatani D, et al. AstraZeneca is not responsible for the privacy policy of any third party websites. Through an agile approach, multidisciplinary team and unique organisational structure, OBI is paving the way for innovative research. Incidence, predictors, and subsequent mortality risk of recurrent myocardial infarction in patients following discharge for acute myocardial infarction. Lifestyle Changes for Heart Attack Prevention. American Heart Association. Remarkably, however, AstraZeneca has the third largest pipeline. 2016. our approach towards holistic care for CVRM patients, https://www.who.int/cardiovascular_diseases/world-heart-day/en/, https://www.usrds.org/2018/view/v2_08.aspx, https://www.heart.org/en/health-topics/heart-attack/life-after-a-heart-attack/lifestyle-changes-for-heart-attack-prevention, https://www.nhs.uk/conditions/heart-attack/prevention/, http://www.healthtalk.org/peoples-experiences/heart-disease/heart-attack/coping-emotions-after-heart-attack, https://www.heart.org/en/health-topics/heart-attack/life-after-a-heart-attack, http://www3.weforum.org/docs/WEF_Harvard_HE_GlobalEconomicBurdenNonCommunicableDiseases_2011.pdf, https://dgk.org/pressemitteilungen/2019-jahrestagung/2019-jt-statements/2019-jt-statements-tag2/neues-versorgungsforschungsprojekt-gullive-r-zur-langzeitversorgung-von-herzinfarkt-patienten-in-deutschland/, Manage other cardiovascular, renal and metabolic diseases and associated risk factors. We are integrated in the drug development teams to influence early on and continue to add value throughout. 2015;132(10):923–31. 3. Available from: URL: https://www.niddk.nih.gov/health-information/health-statistics/kidney-disease. We aspire to move healthcare professionals to treat beyond HbA1C, prevent early cardiovascular and renal complications and explore non-alcoholic steatohepatitis (NASH). Our 40-year heritage in respiratory medicines is just the beginning of our story. J Cardiol 2011; 57(1):8–17. CCC was founded to address the treatment compliance gap, enabling new benchmarks to be set in cardiovascular care. The Global Economic Burden of Non-communicable Diseases. I have read this warning and will not be using any of the contained product information for clinical purposes. Please refer to your approved national product label (SmPC) for current product information. This partnership will see us work hand-in-hand on global policy, advocacy and disease awareness initiatives, supporting global and local activations to assist those at particularly high risk. Supported by the American Heart Association (AHA) and AstraZeneca, One Brave Idea (OBI) aims to understand the molecular events surrounding the earliest transition from wellness to disease in coronary heart disease (CHD). We follow the science to develop innovative treatments and ultimately, modify or even halt the natural course of the disease and regenerate organs. AstraZeneca's boss Pascal Soriot, said: 'The consistent achievements in the pipeline, the accelerating performance of our business and the progress … Circ J. Lindholm D, et al. Available from URL: Di Palo KE, et al. Circulation. 2019. 2017;60(2):259-66. LONDON, UK I March 25, 2020 I AstraZeneca will collaborate with Silence Therapeutics to discover, develop and commercialise small … Our country sites can be located in the AZ Network. 5. (Fast Track, Breakthrough Therapy Designation). 2018 USRDS annual data report: Epidemiology of kidney disease in the United States National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases: Chapter 9: Cardiovascular Disease in Patients With ESRD. World Health Organization. JAMA. 4,5 Atherosclerotic plaque, a build-up of deposits of fatty material, cholesterol, cellular waste products and other substances, accumulate in the coronary arteries, obstructing the blood flow to the heart muscle. 9. J Am Coll Cardiol. Curr Opin Endocrinol Diabetes Obes. [online] Available at: https://www.who.int/cardiovascular_diseases/world-heart-day/en/ [Accessed 31 Jul. Our culture at AstraZeneca. Of the projects targeting priority diseases, the focus is on COVID-19 (3 projects). Collaboration with Silence Therapeutics aims to develop novel, targeted treatments to address significant unmet need. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. The Euro Heart Survey on diabetes and the heart. Phase III/LCM Projects: refers to assets that are pivotal in Phase II/III, or that have been submitted for regulatory approval, and may include assets that are now launched in one or more major markets (removed when launched in all applicable major markets). COVID-19 is caused by a virus called coronavirus (SARS CoV 2). Sacco et al. R.L. We’re constantly pushing the boundaries of science to deliver life-changing medicines to patients, with a passion for discovery and a pipeline to show for it. Just launched in partnership with DGK-Zentrum, the programme provides counselling and lifestyle change support for patients and their treatment, whether risk stratification or routine management.20. This website is intended for people seeking information on AstraZeneca's worldwide business. AstraZeneca to discover and develop siRNA therapeutics for Cardiovascular, Renal, Metabolic and Respiratory diseases in new collaboration. Available at. An exciting and balanced pipeline underpinned by great science. Jernberg T, et al. 2019. PORTFOLIO AND PIPELINE AstraZeneca has a mid-sized portfolio of rele-vant products, with 41 medicines and one pre-ventive vaccine, and a mid-sized pipeline of 16 United States Renal Data System. Click ‘cancel’ to return to AstraZeneca’s site or ‘continue’ to proceed. AstraZeneca and Ionis have a strategic alliance focused on leveraging antisense technology to discover and develop antisense therapies for cardiovascular, metabolic and renal diseases. OBI is turning its focus upstream and seeking out earlier changes in the development of CHD, working outside the constraints of traditional biomedical science. 11. 2013;77(2):439-46. AstraZeneca has said that they’re aware of 15 events of deep vein thrombosis and 22 events pulmonary embolisms, but that’s in 17 million people who have had at least one shot – … Learn more about patients living with chronic kidney disease. The Lancet 2016; 388(10053):1459–544. We have a strong pipeline with more than 33,000 patients participating in Phase I-IV respiratory clinical trials across the world. June 2019. Prog Cardiovasc Dis. United States Renal Data System. AstraZeneca is following the science of common pathways and underlying disease drivers from respiratory disease into immunology-driven disease areas. World Heart Day. 1. A number of advances for AstraZeneca’s drugs have been confirmed. National Institutes of Health [cited 2018 Aug 28]. The Heart of 25 by 25: Achieving the Goal of Reducing Global and Regional Premature Deaths from Cardiovascular Diseases and Stroke. Implementation of a Patient Navigator Program to Reduce 30-day Heart Failure Readmission Rate. On our Keep Treating portal, we answer questions our patients and healthcare professionals may have and emphasise the importance of their relationship in minimising and managing the risk of a second heart attack. Bartnik M, et al. Up to one in five people who have been event-free for a year may experience another heart attack within three years of the first.10 Working together with healthcare professionals, we help raise awareness of the importance of secondary prevention among heart attack survivors. Working on a strong pipeline means so much more than … Wang H et al. ... Area under investigation:cardiovascular outcomes trial in patients with coronary artery disease and type-2 diabetes without a previous history of myocardial infarction or stroke You are about to access AstraZeneca historic archive material. Cardiovascular AstraZeneca has been driving cardiovascular innovation for more than 100 years. Available from URL: Bloom DE, et al. AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. people die from CVRM diseases each year, making them the leading causes of death across the globe5,6, of people with type-2 diabetes in the US have at least one other cardiovascular, renal or metabolic condition7, of patients with heart failure also have chronic kidney disease8, of patients hospitalised for heart failure have diabetes9. 2. Available from: URL: https://www.usrds.org/2018/view/v2_08.aspx. We strive to prevent heart disease onset, as well as treat and regenerate the heart to help protect millions of people living with heart failure. Diabetes Obes Metab 2018; 20(8):2000–3. 2014, Article ID 937398, 21 pages, 2014. https://doi.org/10.1155/2014/937398. Sanofi is a dynamic organisation that is working to meet the healthcare needs of people in the moments that matter AstraZeneca provides this link as a service to website visitors. Discover Sanofi's products in the UK. We aim to treat life-threatening complications and halt disease progression to provide millions of patients living with chronic kidney disease with a longer and greater quality of life. National Institute of Diabetes and Digestive and Kidney Diseases. Eur Heart J. AstraZeneca are also developing testicular cancer drug Lynparza which has had positive findings from trials. I am currently leading the global research and early development group for Cardiovascular, Renal and Metabolism (CVRM) in BioPharmaceuticals R&D at AstraZeneca. Any reference in these archives to AstraZeneca products or their uses may not reflect current medical knowledge and should not be used as a source of information on the present product label, efficacy data or safety data. Forxiga (dapagliflozin) has been recommended for an indication extension of its marketing authorisation in the European Union for the treatment of symptomatic chronic heart failure with reduced ejection fraction in adults with and without type-2 diabetes (T2D). Available at:  https://www.ahajournals.org/doi/full/10.1161/CIR.0000000000000395 Last accessed July 2019. Arnold SV et al. The Patient Navigator Program is a transition-care improvement initiative implemented in 35 US hospitals designed to reduce the 30-day all-cause readmission rate following hospitalised heart failure, improving patients’ long-term outcomes,19 which may also lead to reduction of regulatory penalties and optimised financial results for hospitals. Cardiovascular, Renal and Metabolism (CVRM). With a strong purpose, an even stronger bond between each of our people and a science-led, patient-first attitude, we’re changing the future of medicine and the … We encourage you to read the privacy policy of every website you visit. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective. Eur Heart J. 4. Available from URL: Bhatt DL, et al. We are AstraZeneca, one of the world’s most forward-thinking and connected BioPharmaceutical companies. Up to 94% of people with type-2 diabetes in the US have at least one additional CVRM condition.7 We work to provide solutions for these complications that might become life-threatening, to change the lives of type-2 diabetes patients by reducing risk factors through early prevention. Report a Side Effect uk-drugsafety@sanofi.com +44 (0) 800 0902314 (Monday - Friday) Fax: +44 (0) 800 4716122 Please note, we cannot provide medical advice on your symptoms. 2018 USRDS annual data report: Epidemiology of kidney disease in the United States National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases: Chapter 9: Cardiovascular Disease in Patients With ESRD; 2018. Senior Vice President, CVRM, BioPharmaceuticals Business Unit, SVP, Late-Stage Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, SVP, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D. Respiratory is one of AstraZeneca’s three main therapy areas. Since launching in Kenya in 2014, then Ethiopia in 2016, Tanzania in 2018 and Ghana in 2019, we have conducted over 11 million blood pressure screenings; identified over 2 million elevated readings; trained over 5,800 healthcare workers; and activated over 700 healthcare facilities.12 In support of the United Nations targets to reduce the risk of premature death from NCDs,13 we aspire to reach 10 million people with elevated blood pressure across Africa by 2025. Eur Heart J. We aim to raise awareness of common comorbidities and inspire healthcare professionals and patients alike to get involved in our holistic approach towards disease management. Global, Regional, and National Burden of Cardiovascular Diseases for 10 Causes, 1990 to 2015. AstraZeneca has pushed the boundaries of science and helped millions of patients with respiratory disease. To tackle key issues in cardiovascular care and associated complications, AstraZeneca has entered a multi-year partnership with World Heart Federation (WHF), the world’s leading voice for cardiovascular health. Visit keeptreating.com to learn about the journey of those who want to avoid experiencing a heart attack.
Woelki News Heute, Plot Against America List Of Episodes, Mindustry Save Editor, Der Herr Der Ringe: Die Zwei Türme, Konservative Katholische Vereinigungen, How Does Paine Use Past Examples To Develop His Argument, Nejhlubší Africké Jezero,